GANX

Gain Therapeutics, Inc.

Price Chart

Latest Quote

$1.77

-0.08 (-4.32%)

Current Price

Previous Close	$1.85
Open	$1.83
Day High	$1.90
Day Low	$1.77
Volume	378,602

Fetched: 2026-06-23T21:25:51

Stock Information

Shares Outstanding	42.65M
Total Debt	$672K
Cash Equivalents	$16.54M
Net Income	$-21.24M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$75.50M
EPS (TTM)	$-0.58
Exchange	NGM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$63.04M
Income	$-21.24M
Book/sh	$0.33
Cash/sh	$0.39
Employees	20

Financial Ratios

Quick Ratio	4.51
Current Ratio	4.69
Debt/Eq	4.80

Returns & Margins

ROA	-81.15%
ROE	-214.69%

Ownership

Insider Ownership	2.29%
Institutional Ownership	19.25%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-2.95
P/B	5.36

Analyst Data

Recommendation	none
Target Price	$7.20

Technical Indicators

SMA20	$1.79
SMA50	$1.84
SMA200	$2.20
RSI	45.83
ATR	0.1137

Shares Float	41.65M
Short Float	7.67%
Short Ratio	5.13
Volatility	0.16
Rel Volume	0.54

Performance History

Week	+1.14%
Month	+1.14%
Quarter	-6.35%
6 Months	-21.33%
YTD	-44.34%
Year	+0.00%
3 Years	-63.66%
5 Years	-81.33%
10 Years	-85.49%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-23	$1.77	378,602
2026-06-22	$1.85	798,200
2026-06-18	$1.88	503,900
2026-06-17	$1.78	381,700
2026-06-16	$1.79	600,700
2026-06-15	$1.75	447,100
2026-06-12	$1.68	482,900
2026-06-11	$1.69	534,000
2026-06-10	$1.64	362,300
2026-06-09	$1.65	1,305,700
2026-06-08	$1.69	545,600
2026-06-05	$1.70	616,700
2026-06-04	$1.86	369,400
2026-06-03	$1.79	374,800
2026-06-02	$1.83	887,600
2026-06-01	$1.96	1,154,700
2026-05-29	$1.95	868,700
2026-05-28	$2.02	1,574,300
2026-05-27	$1.77	697,500
2026-05-26	$1.82	1,157,600

About Gain Therapeutics, Inc.

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. The company has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.

📰 Latest News

Gain Therapeutics expands ‘compelling’ evidence base for Parkinson’s candidate

Simply Wall St. • 2026-05-27T04:34:46Z

3 Parkinson's Biotech Stocks Analysts Think Are Wildly Mispriced

Simply Wall St. • 2026-05-22T00:58:40Z

Gain Therapeutics (GANX) Shares Edge Higher After Narrower-Than-Expected Q1 Loss

InvestorsHub • 2026-05-11T13:51:33Z

3 US Biotechs Developing Parkinson’s Therapies

Simply Wall St. • 2026-05-05T03:51:34Z

Gain Therapeutics Highlights GT-02287 Biomarker Signals, Eyes Phase 2 Start in Q3 at Roth Conference

MarketBeat • 2026-03-24T20:34:01Z

Gain Therapeutics (GANX) Upgraded to Buy: Here's Why

Zacks • 2025-12-22T17:00:03Z

Here's Why Gain Therapeutics, Inc. (GANX) is a Great Momentum Stock to Buy

Zacks • 2025-12-08T17:00:05Z

Gain Therapeutics’ (GANX) Preclinical Momentum Drives Its Progress in Parkinson’s Drug Development

Insider Monkey • 2025-11-29T06:26:10Z

Gain Therapeutics (GANX) Upgraded to Buy: Here's What You Should Know

Zacks • 2025-11-17T17:00:03Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$55,180	$140,108
Operating Revenue	$0	$0	$55,180	$132,640
Expenses
Total Expenses	$18,710,702	$20,350,592	$22,308,313	$17,917,153
Other Income Expense	$-833,673	$119,120	$-429,346	$-96,074
Net Non Operating Interest Income Expense	$244,394	$357,096	$494,234	$375,357
Operating Expense	$18,710,702	$20,350,592	$22,308,313	$17,917,153
General And Administrative Expense	$8,497,920	$9,559,534	$10,787,700	$9,539,863
Total Other Finance Cost	-	-	-	$-375,357
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-20,161,099	$-20,411,191	$-22,267,520	$-17,590,738
Net Interest Income	$244,394	$357,096	$494,234	$375,357
Interest Income	$244,394	$357,096	$494,234	$375,357
Normalized Income	$-19,502,497	$-20,505,296	$-21,928,337	$-17,495,173
Net Income From Continuing And Discontinued Operation	$-20,161,099	$-20,411,191	$-22,267,520	$-17,590,738
Total Operating Income As Reported	$-18,710,702	$-20,350,592	$-22,253,133	$-17,777,045
Net Income Common Stockholders	$-20,161,099	$-20,411,191	$-22,267,520	$-17,590,738
Net Income	$-20,161,099	$-20,411,191	$-22,267,520	$-17,590,738
Net Income Including Noncontrolling Interests	$-20,161,099	$-20,411,191	$-22,267,520	$-17,590,738
Net Income Continuous Operations	$-20,161,099	$-20,411,191	$-22,267,520	$-17,590,738
Pretax Income	$-19,299,981	$-19,874,376	$-22,188,245	$-17,497,762
Interest Income Non Operating	$244,394	$357,096	$494,234	$375,357
Operating Income	$-18,710,702	$-20,350,592	$-22,253,133	$-17,777,045
Per Share
Diluted EPS	$-0.61	$-0.89	$-1.71	$-1.48
Basic EPS	$-0.61	$-0.89	$-1.71	$-1.48
Other
Tax Effect Of Unusual Items	$-175,071	$25,015	$-90,163	$-509
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-17,782,983	$-20,385,641	$-21,740,208	$-17,616,803
Total Unusual Items	$-833,673	$119,120	$-429,346	$-96,074
Total Unusual Items Excluding Goodwill	$-833,673	$119,120	$-429,346	$-96,074
Reconciled Depreciation	$94,046	$84,071	$83,579	$64,168
EBITDA (Bullshit earnings)	$-18,616,656	$-20,266,521	$-22,169,554	$-17,712,877
EBIT	$-18,710,702	$-20,350,592	$-22,253,133	$-17,777,045
Diluted Average Shares	$32,968,336	$22,881,415	$13,011,361	$11,883,368
Basic Average Shares	$32,968,336	$22,881,415	$13,011,361	$11,883,368
Diluted NI Availto Com Stockholders	$-20,161,099	$-20,411,191	$-22,267,520	$-17,590,738
Tax Provision	$861,118	$536,815	$79,275	$92,976
Gain On Sale Of Security	$-833,673	$119,120	$-429,346	$-96,074
Research And Development	$10,212,782	$10,791,058	$11,520,613	$8,377,290
Selling General And Administration	$8,497,920	$9,559,534	$10,787,700	$9,539,863
Other Gand A	$8,497,920	$9,559,534	$10,787,700	$9,539,863

Fetched: 2026-06-22

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$18,461,911	$7,205,306	$12,384,849	$18,665,547
Total Assets	$22,818,975	$12,123,884	$18,609,331	$24,099,387
Total Non Current Assets	$581,837	$521,406	$830,463	$3,008,091
Other Non Current Assets	$69,994	$63,804	$51,911	$48,324
Goodwill And Other Intangible Assets	$102,837	$134,268	$193,375	$213,967
Other Intangible Assets	$102,837	$134,268	$193,375	$213,967
Current Assets	$22,237,138	$11,602,478	$17,778,868	$21,091,296
Prepaid Assets	$596,817	$450,852	$741,638	$761,424
Receivables	$802,693	$765,763	$242,577	$191,307
Other Receivables	$622,992	$494,684	-	$87,430
Taxes Receivable	$179,701	$271,079	$242,577	$103,877
Cash Cash Equivalents And Short Term Investments	$20,837,628	$10,385,863	$16,794,653	$20,138,565
Cash And Cash Equivalents	$20,837,628	$10,385,863	$11,794,949	$7,311,611
Cash Equivalents	$11,060,391	$4,745,080	$6,767,291	$4,401,165
Cash Financial	$9,777,237	$5,640,783	$5,027,658	$2,910,446
Investmentin Financial Assets	-	-	$0	$1,941,488
Non Current Prepaid Assets	-	-	-	-
Current Deferred Assets	-	-	-	-
Restricted Cash	-	-	-	-
Accounts Receivable	-	-	-	-
Debt
Total Debt	$732,067	$653,015	$1,027,398	$1,274,257
Long Term Debt And Capital Lease Obligation	$511,322	$381,925	$678,908	$937,042
Long Term Debt	$300,084	$328,327	$449,053	$495,258
Current Debt And Capital Lease Obligation	$220,745	$271,090	$348,490	$337,215
Current Debt	$100,869	$110,177	$118,797	$108,135
Other Current Borrowings	$100,869	$110,177	$118,797	$108,135
Liabilities
Total Liabilities Net Minority Interest	$4,254,227	$4,784,310	$6,031,107	$5,219,873
Total Non Current Liabilities Net Minority Interest	$901,831	$872,989	$1,081,148	$1,094,622
Non Current Deferred Liabilities	$0	$47,441	$94,786	$0
Current Liabilities	$3,352,396	$3,911,321	$4,949,959	$4,125,251
Current Deferred Liabilities	$43,089	$270,704	$1,171,103	$162,491
Current Deferred Taxes Liabilities	$43,089	$18,493	$48,965	$107,311
Payables And Accrued Expenses	$3,088,562	$3,369,527	$3,430,366	$3,625,545
Payables	$992,920	$1,175,578	$1,687,310	$1,882,898
Other Payable	$167,893	$229,319	$368,345	$256,798
Accounts Payable	$825,027	$946,259	$1,318,965	$1,626,100
Equity
Common Stock Equity	$18,564,748	$7,339,574	$12,578,224	$18,879,514
Total Equity Gross Minority Interest	$18,564,748	$7,339,574	$12,578,224	$18,879,514
Stockholders Equity	$18,564,748	$7,339,574	$12,578,224	$18,879,514
Gains Losses Not Affecting Retained Earnings	$776,869	$-247,549	$247,241	$35,627
Other Equity Adjustments	$776,869	$-247,549	$247,241	$35,627
Retained Earnings	$-101,356,007	$-81,194,908	$-60,783,717	$-38,516,197
Other
Ordinary Shares Number	$42,073,807	$27,132,588	$16,206,680	$11,883,368
Share Issued	$42,073,807	$27,132,588	$16,206,680	$11,883,368
Tangible Book Value	$18,461,911	$7,205,306	$12,384,849	$18,665,547
Invested Capital	$18,965,701	$7,778,078	$13,146,074	$19,482,907
Working Capital	$18,884,742	$7,691,157	$12,828,909	$16,966,045
Capital Lease Obligations	$331,114	$214,511	$459,548	$670,864
Total Capitalization	$18,864,832	$7,667,901	$13,027,277	$19,374,772
Additional Paid In Capital	$119,139,677	$88,779,318	$73,113,079	$57,358,895
Capital Stock	$4,209	$2,713	$1,621	$1,189
Common Stock	$4,209	$2,713	$1,621	$1,189
Preferred Stock	$0	$0	$0	$0
Employee Benefits	$390,509	$443,623	$307,454	$157,580
Non Current Pension And Other Postretirement Benefit Plans	$390,509	$443,623	$307,454	$157,580
Non Current Deferred Revenue	$0	$47,441	$94,786	$0
Long Term Capital Lease Obligation	$211,238	$53,598	$229,855	$441,784
Current Deferred Revenue	$0	$252,211	$1,122,138	$55,180
Current Capital Lease Obligation	$119,876	$160,913	$229,693	$229,080
Current Accrued Expenses	$2,095,642	$2,193,949	$1,743,056	$1,742,647
Net PPE	$409,006	$323,334	$585,177	$804,312
Accumulated Depreciation	$-183,765	$-123,357	$-92,797	$-53,329
Gross PPE	$592,771	$446,691	$677,974	$857,641
Leases	$36,098	$31,616	$33,992	$31,437
Other Properties	$379,295	$255,415	$497,263	$696,827
Machinery Furniture Equipment	$177,378	$159,660	$146,719	$129,377
Properties	$0	$0	$0	$0
Other Short Term Investments	-	$0	$4,999,704	$12,826,954
Investments And Advances	-	-	$0	$1,941,488
Available For Sale Securities	-	-	-	$1,941,488
Current Provisions	-	-	-	-

Fetched: 2026-06-22

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-18,465,432	$-18,896,320	$-18,881,231	$-14,811,092
Operating Activities
Operating Cash Flow	$-18,465,432	$-18,873,827	$-18,865,873	$-14,692,139
Cash Flow From Continuing Operating Activities	$-18,465,432	$-18,873,827	$-18,865,873	$-14,692,139
Operating Gains Losses	-	-	-	-
Investing Activities
Investing Cash Flow	$0	$4,977,507	$10,222,667	$-14,774,813
Cash Flow From Continuing Investing Activities	$0	$4,977,507	$10,222,667	$-14,774,813
Capital Expenditure	-	$-22,493	$-15,358	$-118,953
Financing Activities
Issuance Of Capital Stock	$25,470,933	$13,212,311	$12,730,410	$0
Financing Cash Flow	$28,447,766	$13,012,076	$12,641,343	$-78,774
Cash Flow From Continuing Financing Activities	$28,447,766	$13,012,076	$12,641,343	$-78,774
Net Other Financing Charges	$-395,478	$-280,867	-	-
Net Common Stock Issuance	$25,470,933	$13,212,311	$12,730,410	$0
Common Stock Issuance	$25,470,933	$13,212,311	$12,730,410	$0
Net Preferred Stock Issuance	-	-	-	-
Preferred Stock Issuance	-	-	-	-
Other
Repayment Of Debt	$-96,501	$-90,879	$-89,067	$-78,774
Income Tax Paid Supplemental Data	$47,549	$86,309	$134,962	$2,740
End Cash Position	$20,873,924	$10,417,558	$11,828,970	$7,342,429
Beginning Cash Position	$10,417,558	$11,828,970	$7,342,429	$36,911,952
Effect Of Exchange Rate Changes	$474,032	$-527,168	$488,404	$-23,797
Changes In Cash	$9,982,334	$-884,244	$3,998,137	$-29,545,726
Proceeds From Stock Option Exercised	$3,468,812	$171,511	$0	$0
Net Issuance Payments Of Debt	$-96,501	$-90,879	$-89,067	$-78,774
Net Long Term Debt Issuance	$-96,501	$-90,879	$-89,067	$-78,774
Long Term Debt Payments	$-96,501	$-90,879	$-89,067	$-78,774
Net Investment Purchase And Sale	$0	$5,000,000	$10,238,025	$-14,655,860
Sale Of Investment	$0	$5,000,000	$12,194,375	$3,079,495
Net PPE Purchase And Sale	$0	$-22,493	$-15,358	$-118,953
Purchase Of PPE	$0	$-22,493	$-15,358	$-118,953
Change In Working Capital	$-1,006,512	$-1,080,389	$442,230	$1,514,858
Change In Other Working Capital	$-458,639	$-977,628	$1,091,607	$-149,647
Change In Payables And Accrued Expense	$-468,606	$274,889	$-693,698	$1,066,707
Change In Payable	$-468,606	$274,889	$-693,698	$1,066,707
Change In Account Payable	$-468,606	$274,889	$-693,698	$1,066,707
Change In Prepaid Assets	$-79,267	$-377,650	$44,321	$-116,906
Other Non Cash Items	$804,938	$143,523	$-383,188	$-206,861
Stock Based Compensation	$1,803,195	$2,390,159	$3,259,026	$1,526,434
Depreciation Amortization Depletion	$94,046	$84,071	$83,579	$64,168
Depreciation And Amortization	$94,046	$84,071	$83,579	$64,168
Net Income From Continuing Operations	$-20,161,099	$-20,411,191	$-22,267,520	$-17,590,738
Purchase Of Investment	-	$0	$-1,956,350	$-17,735,355
Change In Other Current Liabilities	-	-	$-50,534	$711,073
Change In Receivables	-	-	$-130,068	$3,631
Changes In Account Receivables	-	-	-	$0
Issuance Of Debt	-	-	-	-
Long Term Debt Issuance	-	-	-	-
Depreciation	-	-	-	-
Pension And Employee Benefit Expense	-	-	-	-
Gain Loss On Investment Securities	-	-	-	-

Fetched: 2026-06-22